Category Patents/Designs/Trade Secrets

US Food And Drug Administration Issues Equivalence Guideline For Biosimilars Producers

Biotherapeutic medicines are made out of living organisms and cannot be replicated. No generic medicines, which are exact copies of the reference product, can be made. The generic equivalent of a biotherapeutic would be biosimilars, which are highly similar products. The United States Food and Drug Administration has issued a guide to help producers to prove how close their biosimilars are to the biotherapeutics.

USTR Nominee Lighthizer May Fit Strong Stance On IP Protection

Robert Lighthizer, President-elect Donald Trump's newly named choice for United States Trade Representative, appears to fit Trump's strong stance on China, including on intellectual property protection, but is a longstanding Washington Republican insider and negotiator of trade agreements, which might seem contrary to Trump's stated questioning of the status quo. Still, some say he is apart from Trump's other appointments on trade in important ways.

IP World Enters New Year With Major Shift Of People In Pharma, Copyright

As a new year dawns, a lot of movement has been observed in the pharmaceutical industry with new key players taking the lead. Meanwhile, new delegates are covering IP issues in Geneva, and coordination of regional groups at the World Intellectual Property Organization makes its usual yearly shift for 2017. The copyright industry also saw major changes, and law offices have been busy hiring new partners.

2016 USTR List Of ‘Notorious’ Markets: Stream Ripping, Taobao And Switzerland

The United States Trade Representative’s office today released its annual “notorious markets” for intellectual property-infringing goods, with a list of 21 online and 12 physical markets worldwide. Many of the online sites are based across Europe, including several in Switzerland, but also in Russia and China as in the past. A big feature is China's Taobao, and new methods like stream ripping.

US Supreme Court Eyes Patent-Enforced Post-Sale Restrictions

Few were surprised when, earlier this month, the US Supreme Court agreed to hear the appeal in Impression Products, Inc. v. Lexmark International. The case presents two important patent law issues, and the lower court’s ruling on these issues conflicts with Supreme Court precedents, according to many experts.

Podcast: ITIF’s Atkinson On Trade, Innovation, China In Trump’s Washington

A major shift is underway in Washington that is expected to have ramifications for global trade, innovation, and intellectual property enforcement, as Donald Trump steps into the United States presidency. IP-Watch caught up with Rob Atkinson, president of the Information Technology & Innovation Foundation to get his view on what's to come. Among the predictions: the Washington Consensus on trade gets turned on its head, enforcement will rise including at multilateral level, the US will have many new ideas but iPhones will not be made in the US, and a much-needed "reset" of the US policy on China will bring greater mutual respect - if done right.

UN General Assembly Resolution: TRIPS Flexibilities, High-Level Panel On Medicines Access

The United Nations General Assembly this month is considering a resolution committing to elevate health issues to the highest levels of foreign policy. The resolution includes references and commitments related to dozens of existing instruments and tools aimed at improving health, including a full range of those on access to medicines, such as patent flexibilities under trade rules, and the recent report of the UN Secretary-General’s High-Level Panel on access to medicines and innovation.